May 11, 2021 The Right Honourable Justin Trudeau, P.C., M.P. Prime Minister of Canada 80 Wellington St. Ottawa, ON, K1A 0A2 Subject: Delay and reconsider the PMPRB regulations Dear Prime Minister Trudeau, I am [...]
As we battle the pandemic, we should remember that cancer kills 7,000 Canadians every month and put the same effort into reducing that sad toll. In the three months since COVID-19 started shutting down the [...]
Background Canada has an established publicly funded health care system with a complex drug approval and funding process. After proof of efficacy (POE; key publication/presentation) and before becoming publicly accessible, each drug undergoes a Health [...]
It takes on average 6–12 years to develop new anticancer drugs from discovery to approval. Effective new agents prolong survival. To demonstrate the importance of rapid drug approval, we calculated life-years potentially saved if selected agents [...]
This commentary reviews the evolution of the process of cancer research in the United States over the past 6 decades, from an academic-based to drug industry-based research, and the advantages and concerns. It proposes a [...]
Interesting new research suggests that the burden of proof required by Canada’s health technology assessment (HTA) process for new drugs is too rigid and unfairly excludes many treatments for rare disorders from public drug insurance coverage...
We are concerned Canadians who have been impacted deeply by cancer. One of us (Stewart) is a cancer physician who has seen far too many patients die; the other (Bradford) is a cancer survivor who has recently lost his beloved wife to cancer. She was directly affected by the issues we raise below...